Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Mustang Bio (MBIO) Stock Explodes 260% After FDA Grants Key Cancer Drug Designation

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Mustang Bio Inc (NASDAQ:MBIO) shares are trading sharply higher Monday afternoon. The company earlier saw a positive development as the FDA granted Orphan Drug Designation to its cell therapy candidate, MB-101. Here’s what investors need to know.

What To Know: This designation is for the treatment of aggressive brain cancers, including recurrent diffuse and anaplastic astrocytoma and glioblastoma.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.